The present invention is directed to a novel, industrially viable, cost effective process for manufacturing (5S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide going through a novel intermediate of Formula XXI and XXII.

AN IMPROVED PROCESS FOR PREPARATION OF OLANZAPINE PAMOATE An improved process for preparation of Olanzapine pamoate monohydrate from Olanzpaine is disclosed which comprises mixing at room temperature a solution of Olanzapine prepared in water in presence of an acid, with a solution of pamoic acid prepared in wate...

AN IMPROVED PROCESS FOR PREPARATION OF SUGAMMADEX SODIUM The present invention provides a process for the preparation of Sugammadex sodium involving the step of: reacting 6-perdeoxy-6-per-halo-gamma-cyclodextrin with 3-mercapto propionic acid in the presence of alkali metal alkoxide in an organic solvents. The inve...

The present invention is directed to a novel, facile, concise, industrially viable and cost effective process for the preparation of (5-Nitro-4-thiocyanate pyrimidinl)-3H-benzo(d)-imidazolyl-5-carbonitrile a compound of formula I.

The present invention is directed to a novel, industrially viable and cost effective process for manufacturing (3S)-1 -[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-a,a-diphenyl-3-pyrrolidineacetamide hydrobromide also known as Darifenacin hydrobromide

The present invention relates to process for the preparation of enantiomerically pure (S,S)-2,8-Diazabicyclo [4.3.0] nonane of Formula I and consequent conversion to Moxifloxacin hydrochloride monohydrate.

The present invention relates to a novel, industrially viable and cost effective process for preparation of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, commonly known as Rosuvastatin calcium.

The present invention is directed to an novel, industrially viable and cost effective process for preparation of substantially pure form of 2-butyl-3-[[2"-(lH-tetrazol-5-yl)[l,1-biphenyl]-4-yl]methyl]-l,3-diazaspiro[4.4]non-l-en-4-one commonly known as Irbesartan.

The present invention relates to a simple and efficient method for manufacturing stable anhydrous form B of substantially pure (la,2B,4B,5a,7B)-7-[(hydroxydi-2-thienylacteyl)oxy]- 2,,4 9,9-dimethyl-3-oxa-9-azaniatricyclo[3.3.1.0 ' ] nonane-bromide i.e. Tiotropium bromide, with a purity level of 99.99% and which is...

NA

The present invention relates to a novel, industrially viable and cost effective process for manufacturing of substantially pure anhydrous Form B of 7-[4-[4-(2,3-dichlorophenyl)-l-piperazinyl]butoxy]-3,4-di-hydrocarbostyril also known as Aripiprazole

The present invention is directed to an novel, industrially viable and cost effective process for preparation of substantially pure N-[[trans-4-(l-methylethyl) cyclohexyl] carbonyl]-D-phenylalanine commonly known as Nateglinide.

The present invention encompasses the method of purification of Darifenacin Hydrobromide using purified water and its process for preparation using novel intermediates.

The present invention relates to a simple efficient and cost effective process for commercial manufacture of (E)-3-[2-Butyl-l-{(4-carboxyphenyl) methyl}-IH-imidazole-5-yl]-2-(thiophen-2-ylmethyl)prop-2-enoic acid and its conversion to substantially pure anhydrous mesylate salt with a purity level of 99.85% and singl...

The present invention relates to a novel industrially viable, cost effective process to manufacture substantially pure form of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1 -(1H-1,2,4-triazol-l-yl)butan-2-ol (Voriconazole) with a chiral purity level of greater than 99.9% and impurity level of less than...

The present invention relates to a novel, industrially viable and cost effective process for preparation of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, commonly known as Rosuvastatin calcium.

The present invention encompasses a process for the preparation and purification of cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methxoy]phenyl]-1 -piperazinyl]phenyl]-2,4-dihydro-2-( 1 -methylpropyl)-3H-1,2,4-triazol-3-one of formula I to obtain a specifically desired fo...

The present invention relates to an improved, cost effective, eco-friendly and easy to handle process to manufacture substantially pure form of (2E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide or (E)- N,N-diethyl-2-cyano-3-(3,4-dihyroxy-5-nitrophenyl)-acrylamide polymorphic form A commonly know...

The present invention is directed to an improved industrially viable, cost effective process to manufacture substantially pure form of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-(lH-l,2,4-triazol-l-yl)butan-2-ol (Voriconazole) with a chiral purity level of greater than 99.9% and impurity level of le...

The present invention is directed to an improved industrially viable, cost effective process for manufacturing pure racemic crystalline anhydrous form of (l-benzyl-4-(5,6,-dimethoxyindanone-2yl)methylpiperidine) hydrochloride Form III commonly known as Donepezil hydrochloride with a purity level of greater than 99.9...

The present invention relates to a simple efficient and cost effective process for commercial manufacture of (E)-3-[2n-butyl-l-((4-carboxyphenyl) methyl}-lH-imidazole-5-yl]-(2-thienyl)methyl"2-propenioc acid and its conversion to substantially pure anhydrous mesylate salt as shown in Formula I, with a purity level o...

ABSTRACT The present invention relates to an improved simple, efficient and cost effective process for the commercial manufacture of (αS)-α-Ethyl-2-oxo-l-pyrrolidineacetamide and improved processes for the preparation thereof.

An improved process for the preparation of Elagolix Sodium having the structural formula (I). The present invention relates the novel intermediates useful in the preparation of Elagolix Sodium.

An improved process for the preparation 2-aminobutyramide of formula (I) by continuous flow technology. The above intermediate of formula (I) is to provide process with lower operational expenditure, higher yield and higher purity. The compound of formula (I) is used as an intermediate in the synthesis of...

Abstract An improved process for the preparation of Brivaracetam having the structural formula (I).

Improved process for the preparation of Liraglutide having the structural formula (I). His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Glu-Palmitoyl)-Glu-Phe-lle-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH Formula-I The present invention relates to novel fragments-2 and -4 which are us...

Novel process for the preparation of Brivaracetam having the structural formula (I). The present invention also provides a novel compound of formula (IV). wherein X is a halogen and R is alkyl, cycloalkyl, alkoxy, aryloxy, aryl or alkylaryl. The present invention also provides process for the pr...

The present invention provides a process for the preparation of Lacosamide impurities.

The present invention provides a process for the preparation of Indacaterol acetate of Formula-I, The present invention also provides a novel crystalline form of Indacaterol acetate.

The present application relates to supra-molecular complex of valsartan and sacubitril which is known as LCZ696 and process for the preparation thereof.

The present invention discloses a process for the preparation of Sacubitril of Formula I and its novel intermediates.

The present invention provides a process for the preparation of (5-(4-cyanophenoxy)-l-hydroxy-l,3- dihydro-2, l-benzoxaborole having formula (I).

The present invention relates to an improved process for the preparation of Sugammadex sodium of formula-(I) (I)

The present invention relates to a process for large scale liquid phase synthesis of Octreotide acetate of formula (I). The invention also relates to process of preparation of novel intermediates of formula (A), formula (B) and formula (C) used in the synthesis of Octreotide acetate of formula (I). ...

The present invention relates to commercial scale manufacturing process for the preparation of 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro carbostyril monohydrate having formula (I).

ABSTRACT The present invention provides a process for the preparation of Itraconazole intermediate compound of formula I

The present invention relates to an improved process for the preparation of (5-(4-cyanophenoxy)-l-hydroxy-l,3- dihydro-2, l-benzoxaborole having formula (I). (I) The present invention also relates to novel intermediates which is useful in the preparation of Crisaborole of formula-I. ...

An improved process for the preparation of Elagolix Sodium having the structural formula (I). The present invention relates the novel intermediates and salts useful in the preparation of Elagolix Sodium.

An improved process for the preparation of Indacaterol Maleate having the structural formula (I). The present invention also relates to an improved process for the preparation of benzyl intermediate of Formula IV.

An improved process for the preparation of Mirtazapine having the structural formula (I). The present invention relates the novel intermediate of formula (V), which is useful in the preparation of Mirtazapine. (V)

Abstract The present invention relates to improved process for the preparation of 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril monohydrate having formula (I).

The present invention relates to an improved process for the preparation of Vilanterol trifenatate having the structural formula-I using novel succinate salt of Vilanterol intermediate. The present invention also relates to novel succinate salt of Vilanterol intermediate having the structural formula-V and proce...

An improved process for the preparation of Elagolix Sodium having the structural formula (I). The present invention relates to highly pure compound of formula-VI as a solid which is useful in the preparation of Elagolix sodium. The present invention provides a stable, simple and commercially viabl...

An improved proves for the preparation of Tafamidis meglumine having the structural formula I. The present invention also provides an improved process for the preparation of Tafamidis of formula Ia. The present invention also provides an improved process for the preparation of Tafamidis intermediate of f...

Improved process for the preparation of Semaglutide having the structural formula (I). His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys (C18 di acid mono-t-butyl-?-Glu(AEEA-AEEA)-OtBu)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH Formula-I The present invention relates to the...

The present invention relates to a novel crystalline Form-N of Tafamidis free acid of formula I. The present invention also relates to a process for the preparation of novel crystalline form-N of Tafamidis free acid of formula-I.

Abstract The present invention relates to an improved process for the preparation of Tapinarof compound of Formula-I. which comprises: Reacting of Methyl 3,5-dimethoxy benzoate compound of Formula-1 with Isopropanol to obtain Methyl 3,5-dimethoxy-4-isopropylbenzoate compound of Formula-2; reduction of Methyl 3...

Abstract Improved process for the preparation of Semalinker having the structural formula (I). Formula-I The present invention also relates to the following fragments which are useful in the preparation of Semalinker. Fragment-1: Fmoc-Lys(AEEA-NH2)-OH Fragment-2: Z-Glu(AEEA-OSu)-OtBu Fragment-3: OtB...

The present invention relates to an improved process for the preparation of Finerenone compound of Formula-I. The present invention also relates to novel intermediate compounds of Formula-IV, VI, VII & VIII used in the preparation of Finerenone compound of Formula-I The present invention also ...

The present invention relates to an improved process for the preparation of Tapinarof compound of Formula-I. The present invention also relates to novel intermediate compound of Formula-5 used in the preparation of Tapinarof compound of Formula-I The present invention also relates to process for the ...

The present invention relates to Adipic acid cocrystals of Voxelotor of Formula I. I The present invention also relates process for the preparation of Adipic acid cocrystals of Voxelotor.

Abstract An improved process for the preparation of Roxadustat having the structural formula I. The present invention also provides a process for the preparation of Roxadustat intermediate having the structural formula Ia.

The present invention relates to an improved process for the preparation of Tapinarof compound of Formula – I. Which comprises: Reacting of Methyl 3,5-dimethoxy benzoate compound of Formula-1 with Isopropanol to obtain Methyl 3,5-dimethoxy-4-isopropylbenzoate compound of Formula-2; reacting Methyl 3,5-dimethoxy...

The present invention discloses an improved process for the preparation of Difelikefalin Acetate having the structural Formula I. Formula I The present invention also discloses novel intermediate compounds of Formula IIIb, Formula IVb, Formula Vb and Fragment 2, and their preparation processes. wherein, R2...

An improved process for the preparation of Tirzepatide having the chemical structural Formula I. The present invention also relates to novel Fragments-2, 3, 4, 5 and its process of preparation. The present invention also relates to novel compounds of Formulae II, III, IIIa, V, Va and its pro...

Abstract An improved process for the preparation of Tirzepatide by a linear synthesis having the chemical structural Formula I. The present invention also relates to novel intermediates of Formula II, III and its process for preparation. Formula II: Boc- Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-Phe-Thr(tBu)-...

Abstract Improved process for the preparation of Difelikefalin Acetate having the structural Formula I. which comprises: anchoring Boc-Pip(Fmoc)-OH to a resin in presence of a base, coupling of Fmoc-D-Lys(Boc)-OH to a resin in presence of coupling agent in a solvent to obtain dipeptide resin followed by sequ...

Abstract The present invention relates to an improved process for the preparation of sterile Brinzolamide compound of Formula-I by using Aluminium Canister and Aluminium foil. The present invention also relates to an improved process for the preparation of sterile Brinzolamide compound of Formula-I by usin...

The present invention relates to an improved process for the preparation of Finerenone compound of Formula I. The present invention also relates to novel intermediate compounds of Formula II, III IV, V & VI and its process for the preparation.

An improved process for the preparation of Edaravone of Formula I, comprising the steps of: i) reacting the phenyl hydrazine with ethyl acetoacetate in methanol and water as solvent, triethylamine as base to obtain a reaction mass containing Edaravone; ii) isolating Edaravone from the reaction mass obtained in ste...

Abstract An improved process for the preparation of Tirzepatide having the chemical structural Formula I. The present invention also relates to the compounds of SEQ ID NO. 1 to 14 or a pharmaceutically acceptable salt thereof for use in the synthesis of Tirzepatide or a pharmaceutically acceptable salt thereof....

The present invention relates to an improved process for the preparation of Edoxaban Tosylate of compound of Formula I. Which comprises: Condensation of 2-Amino-5-chloropyridine compound of Formula-2 with Ethyl oxalyl chloride of Formula-3 to obtain Ethyl 2-((5-chloropyridin-2-yl) amino)-2-oxoacetate compou...

An improved process for the preparation of (S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine(2R,3R)-2,3 bis(benzoyloxy) succinic acid compound of Formula I. Imine formation of compound of Formula II with n-propylamine and acetic acid in presence of methanol to obtain compound of Formula III. Reduct...

Abstract The present invention relates to process for the preparation of Tapinarof form-1 from Tapinarof form-II by dissolving in methanol and water.

Abstract The present invention relates to an improved process for the preparation of Tapinarof compound of Formula-I. Which comprises: Reacting of 3,5-dihydroxy-4-isopropylbenzoic acid compound of Formula-1 with chloromethyl methyl ether (MOM-Cl) to obtain Methoxymethyl 4-isopropyl-3,5-bis (methoxymethyl) benz...

An improved process for the preparation of Rotigotine compound of Formula I with resolving agents. Imine formation of compound of Formula II with n-propylamine and acetic acid in presence of solvent to obtain compound of Formula III(a). Reduction of compound of Formula IIIa with reducing agent to obtain co...

An improved process for the preparation of Edaravone of Formula I, comprising the steps of: i) reacting the phenyl hydrazine with ethyl acetoacetate in methanol and water as solvent, triethylamine as base to obtain a reaction mass containing Edaravone; ii) isolating Edaravone from the reaction mass obtained in ...

Abstract The present invention relates to process for the preparation of Apixaban polymorphic form N-1 of formula (I) having a particle size diameter D90 greater than 90 µm with plate shape.

Abstract Novel process for the preparation of Difelikefalin Acetate having the structural Formula I. which comprises: activation of N-protected-D-Phe-OH in presence of activating agent followed by coupling with H-D-Phe-OH to obtain N-protected-D-Phe-D-Phe-OH dipeptide which is sequential activation and coupl...